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ABSTRACT  
         Background and objectives: Globally, about one third of the population has been 
infected with Hepatitis B virus (HBV) and more than 400 million people have become 
chronically infected. Nearly, 20-25% of all carriers develop serious liver diseases such as 
cirrhosis, chronic hepatitis and hepatocellular carcinoma (HCC). According to the World 
Health Organization, HBV infection causes more than one million deaths every year. Co-
infection with Human Immunodeficiency virus (HIV) and HBV is common, since both viruses 
have the same routes of transmission. Approximately 10 -15% of HIV-infected individuals 
develop chronic hepatitis B. The risk of liver diseases-related deaths is also higher in the co-
infected patients. According to previous studies, mutation of the pre-core (PC) and basal-
core promoter (BCP) regions may play an important role in development of HBV-related HCC 
and severe liver disease. The aim of this study was to investigate mutations in the BCP, PC 
and core regions of HBV in HIV-positive patients. 
          Methods: DNA was extracted using commercial kits to determine the BCP, PC/core 
mutations in 124 HIV/HBV co-infected patients (32.4% female and 67.6% male). Polymerase 
chain reaction (PCR) was performed using specific primers. The positive PCR products were 
subjected to automated sequencing. Then, nucleotide sequences were aligned with the 
standard hepatitis B sequence [Gene bank, accession number: AB033559] for mutation 
detection and analysis. 
          Results: In this study, three patients (8.1%) were HBeAg-positive and all of them 
were HBsAg-positive. The mean of CD4 cell count was 120 cells/mL. The mean age of the 
patients was 36.16 years. The important pathological mutations in HBV patients including 
1752A (73%), 1773C (70.3%), 1753C (10.8%), 1896A (8.1%) and 1762T/1764A (2.7%) were 
detected in this study.  
         Conclusion: Identification of mutations in co-infected patients is of greater 
importance compared to mono-infected patients, because it can be useful for prediction of 
HCC-related mutations. Co-infection with HIV has important effects on the natural history of 
HBV infection, and creates different mutational patterns compared to mono-infected 
patients. 
           Keywords: HBV, HIV, Mutation. 
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homosexual men followed by intravenous drug 
users, especially in Iran (8, 9). The rate of 
HBV virion production (up to 10
11
/day) is 
higher than HIV and approximately 10 times 
higher than other DNA viruses. The HBV 
reverse transcriptase does not have 
proofreading activity, and with enormous daily 
virion production, errors occur during 
replication. The error rate of the HBV pol has 
been estimated as 10
-7
 per nucleotide per day. 
Thus, approximately 10
14
 nucleotides are 
replicated daily with potentially 10
7
 base 
pairing errors (10). The core promoter (CP, 
nt1575-1849) of the viral genome plays a 
significant role in HBV replication as it directs 
initiation of transcription for the synthesis of 
both the PC and pre-genomic (pg) RNAs. The 
CP consists of the basal core promoter (BCP, 
nt 1743-1849) and the upper regulatory region 
(nt 1613-1742). The BCP has both positive 
and negative regulatory elements that 
modulate promoter activity (10). It is sufficient 
for precise initiation of both PC mRNA and pg 
RNA transcription in vivo. BCP contains a 
major nuclear binding site, which is 
recognized by different members of the 
nuclear receptors superfamily (including 
PPARα-RXRα heterodimer, HNF4) and a 
series of transcription factors (such as C/EBP) 
to regulate the transcription of the PC and core 
RNAs. The CP overlaps with the 3’-end of the 
X ORF (nucleotide 1374-1836) that affect 
mutations in this region. The 5’-end of the PC 
region also contains cis-acting elements, and 
its transcription regulation is controlled by 
cellular and viral factors. This regulatory 
region exhibits high sequence conservation but 
when variations occur, they may contribute to 
the persistence of HBV within the host, 
leading to chronic infection and cirrhosis. 
Different biological functions of the PC and pg 
RNA, and differential regulation of BCP may 
affect HBV replication and pathogenesis (11-
13). G to A change at nucleotide 1896 is the 
most frequently observed mutation in the PC 
region, which results in a stop codon and 
ultimately leading to premature termination of 
the PC/core protein (precursor of HBeAg). 
This mutation is located within the epsilon (ε) 
structure, a highly conserved stem-loop that is 
crucial for initiation of encapsidation within 
the viral replication cycle. However, this 
mutation pattern in co-infected patients is 
slightly different and less frequent (13, 14). 
 
       Hepatitis B virus (HBV) infection is an 
important health problem in the world. About 
more than one third of the world’s population 
has been infected with HBV. While 2-10% of 
the world’s population are chronic carriers of 
HBV, nearly 25% of them develop serious 
liver diseases such as cirrhosis, chronic 
hepatitis and hepatocellular carcinoma (HCC). 
Hepatitis B infection leads to more than one 
million deaths every year (1-3). Polymerase 
chain reactions (PCR)-based assays and 
genome sequence analysis have shown 
remarkable genetic variability in HBV. 
Currently, 10 genotypes (A–J) and several 
sub-genotypes have been identified, which are 
scattered across different geographical regions 
(4). Although Iran is considered a low 
endemicity country, the prevalence of HBV is 
increasing in the country. The co-infection 
with human immunodeficiency virus (HIV) is 
another important challenge in the healthcare 
system (5). Co-infection with HIV and HBV is 
common, since both viruses are usually 
transmitted through blood-to-blood contact 
and sexual contact. Approximately 10-15% of 
HIV-infected individuals are chronically 
infected with hepatitis B. In highly endemic 
areas like Africa and Asia, the prevalence of 
HBV is even higher (6). It is well 
demonstrated that HIV infection can accelerate 
HBV-associated liver diseases, such as the 
progression of cirrhosis in co-infected 
individuals (4). The risk of death caused by 
liver disease in HIV–HBV co-infected patients 
is 14 times higher than in mono-infected 
patients (7). Different HBV genotypes may 
have distinct impacts on progression of 
acquired immune deficiency syndrome. 
Increasing evidence suggests that HBV 
genotype is an important factor in determining 
HBV disease progression and response to 
antiviral treatment. In addition, certain 
mutations that emerge under medical pressure 
(vaccine or antiviral therapy) made the 
management of HBV infection more difficult 
(7). Mutations in the pre-core (PC)/core 
promoter are not HBV genotype restricted and 
there is limited information available on the 
association between HIV infection and HBV 
mutations in co-infected patients. The route of 
transmission and  prevalence  of  HBV  in 
HIV-positive  patients  are  different.  The 
highest  incidents  of  HBV  transmission  in 
HIV  co-infected  individuals  are  observed  in  
INTRODUCTION 
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The length of amplicon was 390 bp. Briefly, 
100 ng of the extracted DNA was added to an 
amplification mixture containing 1X PCR 
buffer, 1.5Mm MgCl2 , 0.15 Mm dNTP mix , 
2.5 U Taq DNA polymerase (QIAGEN, 
Hamburg, Germany), 0.2pmol/μl of each 
primers and distilled water in a total volume of 
50 μl. Thermal cycling conditions for PCR 
were as follows: initial denaturation at 95˚ C 
for 5 min; 35 amplification cycles 
(denaturation for 1min at 95°C; annealing of 
primers for 1 min at 55°C; extension for 2 min 
at 72°C); and a final extension step for 5 min 
at 72°C. 
Direct sequencing of positive PCR products 
(Macro gene, South Korea) was done to 
determine the BCP and PC/core mutations. 
The PCR products were compared to the 
reference sequence (GenBank, Accession 
number: AB033559) using a BLAST search 
analysis. The nucleotides were translated into 
amino acid sequences using the translation tool 
on NCBI (National Center for Biotechnology 
Information) website and Gene Runner 
software to determine amino acid mutations.  
The data was analyzed using SPSS software 
17.0 (SPSS, Inc., Chicago, IL).  P-values < 
0.05 were considered as statistically 
significant. The study was approved by the 
Research Ethics Committee of Golestan 
University of Medical Sciences.  
 
RESULTS   
      The mean age of patients was 36.16 
(43.2% were <32 years). All patients were 
HBsAg-positive and three (8.1%) were 
HBeAg-positive. The mean of CD4 cell count 
was 120 (cells/μL). There were 70 point 
mutations consisting of 42 (60%) missense 
mutations and 28 (40%) silent mutations, 
which had no effect on the amino acid 
sequence. There were 17 BCP mutations at the 
amino acid level and 25 amino acid changes in 
the PC/core region. 
Some of the high-level mutations such as 
1912T (94.6%) and 1978A (86.5%) were 
silent. The important missenses mutations that 
altered the amino acid were 2003T/2005A 
[(100%) that changes A64S (100%) amino 
acid] and 2020A [(86.5%) that changes D69E 
amino acid]. The main pathologic mutations in 
patients were 1762T/1764A (2.7%), 1896A 
(8.1%), 1753C (10.8%), 1773T (70.3%) and 
1774T (13.5%).  
Isolates with transversion at A1762T together 
with G1764A mutations in the BCP are often 
present in hepatitis B carriers with chronic 
hepatitis, fulminant hepatic failure (FHF) and 
HCC patients but less frequent in inactive 
carriers and immune suppressed patients. The 
1762 and 1764 mutations reduce transcription 
of the PC mRNA by interfering binding of 
transcription factors, which in turn down-
regulates HBeAg synthesis. Some studies have 
shown that genomic mutations at positions 
1727G, 1741C, 1761C, 1757A /1764T 
/1766G, 1773T, 1773T /1775G and 1909C are 
associated with HCC in HBV-infected patients 
(15-19). Several studies have reported an 
association between CP mutations and 
increased risk of liver inflammation, cirrhosis 
(20) and HCC (21). Some studies have 
reported an association between PC mutations 
and fulminant hepatitis (22-24). To our 
knowledge, there are limited reports on HBV 
BCP, PC/core mutations in patients co-
infected with HIV in Iran. The current study 
investigated the mutational patterns of HBV in 
HIV–HBV co-infected patients. 
 
MATERIAL AND METHODS 
       A cross-sectional study was performed to 
identify patients with HIV and HBV co-
infection. Blood samples were collected from 
124 patients with confirmed HIV/HBV 
infection who were referred to HIV Prevention 
Centers in cities of Kermanshah, 
Khorramabad, Tehran and Shiraz. Serum 
samples were collected to identify and confirm 
hepatitis B by serological testing using HBV 
serological markers, enzyme immunoassay 
kits (HBsAg, anti-HBc, and HBeAg) (Dade 
Behring Inc., Delaware, USA) and virological 
analysis. Medical records and demographic 
data including gender, age, CD4 count and 
probable route of HIV transmission were 
collected. The most common route of HIV 
transmission (59.40%) was via intravenous 
drug use along with risky sexual behavior.  
Two hundred μl of serum were used for HBV–
DNA extraction using commercial high pure 
viral nucleic acid kits (Roche, Hamburg, 
Germany), according to manufacturer’s 
instructions. The DNA was amplified by 
polymerase chain reaction (PCR) using the 
following pair of primers (GeNet Bio, Korea):  
Forward   5'ACCTTGAGGCATACTTCAAA-     3'   
Reverse    5'-CAGAATAGCTTGCCTGAGTGC-3'   
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Figure 1- The most common amino acid mutations 
 
Figure 2- The most common nucleotide mutations 
 
Figure 3- The most common deletion and insertion mutations 
35/ Hosseinzadeh Adli and colleagues 
D
ow
nl
oa
de
d 
fro
m
 g
ou
m
s.
ac
.ir
 a
t 8
:5
4 
+0
43
0 
on
 S
un
da
y 
Se
pt
em
be
r 2
0t
h 
20
20
   
   
   
 [ D
OI
: 1
0.1
88
69
/ac
ad
pu
b.m
lj.1
0.4
.32
 ]  
Medical Laboratory Journal, Jul, Agu 2016; Vol 10: No 4 
modes of HIV transmission in Iran are 
intravenous drug use and risky sexual 
behaviors (32, 33). Similarly, the main modes 
of transmission in this study were intravenous 
drug use and history of risky sexual behavior. 
The high rate of HIV infection in married 
patients in the present study highlights the 
need for measures to prevent HIV and HBV 
infection in family of patients. 
Mutation at nucleotide 1762T/1764A 
increased the level of HBV DNA replication 
and pg RNA transcription compared to the 
wild type strain. The serum level of HBeAg in 
the 1762T/1764A mutant group is lower than 
that of the wild type strain. The mutation is 
located in hepatocyte nuclear factor 4 binding 
site. A number of liver transcription factors are 
involved in the regulation of HBV 
transcription and replication (34). The 
mutations at nucleotides 1766T/1768A and 
1896A/1899A are associated with high 
replication levels. Moreover, 1753C and 
1766T mutations are related to high replication 
levels. Apart from the 1753C mutation that has 
been observed in HCC patients, other 
mutations in this study were at low level. HBV 
replication level in HBV/HIV co-infected 
patients is lower compared to mono-infected 
patients. Cassino et al. showed that BCP/PC 
mutations in HIV/HBV patients is lower 
compared to HBV patients (35), which is 
consistent with the findings of the present 
study.  
Some studies determined whole genome HBV 
mutations in co-infected patients. 
Tangkijvanich et al. found no difference in 
mutations, age, gender, and HBeAg and 
alanine transaminase between co-infected and 
mono-infected patients. They reported 1762T, 
G1764A, 1896A and 1753C mutations in 45.8 
%, 50%, 25% and 20.8% of co-infected 
patients, respectively. The rate of 1762T, 
1764A and 1896A mutations in co-infected 
patients in the present study was lower than 
the values reported by Tangkijvanich et al. 
This could be due to geographical differences 
in HBV mutational patterns, since 
different HBV genotypes are associated 
with various mutations in the HBV core 
region(36). Fernando Gallego et al. reported 
no  mutations   at nucleotides  1762, 1764  and  
There were 15 insertion and seven deletion 
mutations. The most common insertion and 
deletion mutations were observed at nucleotide 
1740T (10.8%) and 2069 (21.6%), 
respectively. There was no significant 
association between the age, gender and 
HBeAg of patients, and the patterns of amino 
acid substitutions.  
 
DISCUSSION 
      The co-infection with HIV changes 
intracellular microenvironment and provides 
suitable conditions for HBV that leads to more 
stability and affects mutational patterns. The 
high rate of mutation in HBV compared to 
other DNA viruses is due to lack of HBV 
polymerase proofreading and production of 
large amounts of virus particles. The patients 
co-infected with HIV have higher level of 
hepatitis B viremia, rapid progression to 
chronic hepatitis B and increased risk of 
cirrhosis and HCC compared to mono-infected 
patients (12). The HBV genotype, CP 
mutations, and high viral load are viral factors 
associated with increased risk of HCC. The 
other hotspot CP mutations are 1753A/C/G 
and 1768A, which are also associated with the 
increased risk of HCC. BCP mutations are 
common in HCC patients and there is a high 
rate of point mutations in this region 
(particularly dual V131L and K130M) among 
patients with cirrhosis and HCC (18, 25-27). 
In our study, we identified these mutations in 
two patients that can be indicator of HCC 
progression. Some studies have shown that 
mutation 1762T/1764A suppresses mRNA 
transcription and enhances HBV replication. 
Although CP mutations may enhance HBV 
replication(28), several clinical reports have 
revealed that the presence of 1762T/1764A 
mutation is not always associated with the 
high HBV-DNA levels (29). In the study of 
Chilo L. et al., CD4 counts of patients with 
HIV/HBV infection were significantly lower 
than mono-infected patients (30). Another 
study also demonstrated low amount of CD4 
cells in co-infected patients (31). In the present 
study, the mean number of CD4 cells in 
patients was 120 (cells/μL). This indicates that 
HBV infection has caused a substantial 
decrease in CD4 of co-infected patients. The 
most common route of HIV transmission is 
sexual contact, intravenous drug use and 
perinatal   transmission.   The   most   common  
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in viruses, the virus’s genome remains 
unchanged in suitable host environment. Co-
infection of patients with HIV provides better 
conditions for HBV, which results in low rate 
of mutations in the HBV genome. 
It is recommended to conduct a large-scale 
study in countries with high prevalence of 
HBV/HIV infections, to evaluate clinical and 
virological differences between mono-infected 
and co-infected patients. 
 
CONCLUSION 
        Detection of the mutations in the BCP 
and PC/core regions of HBV in co-infected 
patients could be useful for development of 
better preventive and therapeutic strategies, 
and help predict the progression of liver 
diseases. 
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1896 in HIV/HBV co-infected patients 
(37).However, Yousif et al. reported low 
frequency of these mutations in HIV/HBV 
patients and 88% frequency rate for HBeAg-
negative patients (38), which is in agreement 
with the findings of the present study. 
Mutations at nucleotides 1762, 1764, 1812, 
1809, 1814-1816 and 1809 affect the 
production of HBeAg, which is highly 
immunogenic (39). Since co-infected patients 
with HIV have reduced immune pressure, a 
reduction can be seen in the production and 
secretion of HBeAg. Taffon et al. showed the 
high frequency of BCP and PC pathobiological 
mutations in Italian co-infected patients, while 
several corresponding sites showed amino acid  
variations. Similar to the present study, the 
rate of mutations in the mentioned study was 
not correlated with age and gender. However, 
high rate of 1762, 1764, 1766 and 1809 
mutations is related to different geographical 
distribution of HBV mutations. Different HBV 
genotypes are associated with mutations in 
different regions (40-42). Survival of an 
organism depends on its capacity to cultivate 
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